| MeSH term | MeSH ID | Detail |
|---|---|---|
| Abnormalities, Multiple | D000015 | 13 associated lipids |
| Abortion, Spontaneous | D000022 | 12 associated lipids |
| Acne Vulgaris | D000152 | 35 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Adrenal Insufficiency | D000309 | 3 associated lipids |
| Akinetic Mutism | D000405 | 1 associated lipids |
| Albuminuria | D000419 | 18 associated lipids |
| Alopecia | D000505 | 14 associated lipids |
| Alopecia Areata | D000506 | 6 associated lipids |
| Alzheimer Disease | D000544 | 76 associated lipids |
| Amenorrhea | D000568 | 4 associated lipids |
| Amputation, Traumatic | D000673 | 2 associated lipids |
| Anemia | D000740 | 21 associated lipids |
| Anemia, Aplastic | D000741 | 6 associated lipids |
| Anemia, Hemolytic | D000743 | 4 associated lipids |
| Anemia, Hemolytic, Autoimmune | D000744 | 5 associated lipids |
| Anemia, Refractory | D000753 | 3 associated lipids |
| Anemia, Refractory, with Excess of Blasts | D000754 | 2 associated lipids |
| Aneurysm, Dissecting | D000784 | 2 associated lipids |
| Angiolymphoid Hyperplasia with Eosinophilia | D000796 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Breuer K et al. | Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. | 2005 | Am J Clin Dermatol | pmid:15799678 |
| Gupta AK and Versteeg SG | Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review. | 2017 | Am J Clin Dermatol | pmid:27804089 |
| Kalavala M and Dohil MA | Calcineurin inhibitors in pediatric atopic dermatitis: a review of current evidence. | 2011 | Am J Clin Dermatol | pmid:21067248 |
| Yang LP and Curran MP | Spotlight on topical pimecrolimus in pediatric atopic dermatitis. | 2010 | Am J Clin Dermatol | pmid:20509720 |
| Cheer SM and Plosker GL | Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis. | 2001 | Am J Clin Dermatol | pmid:11770393 |
| Patel TS et al. | Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians. | 2007 | Am J Clin Dermatol | pmid:17645374 |
| Mertens JS et al. | Morphea and Eosinophilic Fasciitis: An Update. | 2017 | Am J Clin Dermatol | pmid:28303481 |
| Frankel HC and Qureshi AA | Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis. | 2012 | Am J Clin Dermatol | pmid:22263704 |
| Iskedjian M et al. | Topical calcineurin inhibitors in the treatment of atopic dermatitis: a meta-analysis of current evidence. | 2004 | Am J Clin Dermatol | pmid:15301573 |
| Kroft EB et al. | Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. | 2009 | Am J Clin Dermatol | pmid:19354332 |
| Siegfried EC et al. | Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. | 2013 | Am J Clin Dermatol | pmid:23703374 |
| Tjioe M et al. | Topical macrolide immunomodulators: a role in the treatment of vitiligo? | 2006 | Am J Clin Dermatol | pmid:16489839 |
| Wellington K and Noble S | Pimecrolimus: a review of its use in atopic dermatitis. | 2004 | Am J Clin Dermatol | pmid:15663345 |
| Ingram JR et al. | Impact of topical calcineurin inhibitors on quality of life in patients with atopic dermatitis. | 2009 | Am J Clin Dermatol | pmid:19489656 |
| Reitamo S et al. | Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. | 2002 | Am J Clin Dermatol | pmid:12113647 |
| Wellington K and Jarvis B | Spotlight on topical pimecrolimus in atopic dermatitis. | 2002 | Am J Clin Dermatol | pmid:12113651 |
| Lübbe J et al. | Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. | 2006 | Am J Clin Dermatol | pmid:16605292 |
| Ellis CN et al. | Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age. | 2006 | Am J Clin Dermatol | pmid:16605293 |
| Wollina U | The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis. | 2007 | Am J Clin Dermatol | pmid:17492844 |
| Kasper RC et al. | Anetoderma arising in cutaneous B-cell lymphoproliferative disease. | 2001 | Am J Dermatopathol | pmid:11285407 |